Prosecution Insights
Last updated: August 18, 2026
Application No. 18/091,139

CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT

Final Rejection §112
Filed
Dec 29, 2022
Priority
Jun 30, 2020 — JP 2020-113429 +2 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fujifilm Holdings Corporation
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
837 granted / 1034 resolved
+20.9% vs TC avg
Moderate +10% lift
Without
With
+9.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
63 currently pending
Career history
1094
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
17.1%
-22.9% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
44.3%
+4.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1034 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The 2026 March 13 amendment containing claims 1-16 is considered. The objection and rejection are overcome because the quality of general formula (P) is now legible and the claims have enabled subject matter for a near-ultraviolet light absorbing compound. Claim Objections Claims 1-16 are objected to because of the following informalities: the multiple uses of the phrase “may be” in relation to multiple variables forming rings with each should be written as --can be-- to show a proper alternative. This objection applies to variables Z1, Z2, Ax, Ay, Xa, and Xb. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The structural metes and bounds of variables Spa and Spb are unclear. The claims define them each as “a linking group having a shortest atom number of 2 or more”. This definition does not state what elements are part of the linking group, only that 2 or more of a group are required. Although these variables are discussed in the specification, the recited groups do not limit claim 1 (specification, page 20, paragraph [0058] to page 21, paragraph [0060]). The structural metes and bounds of variable Spc are unclear. The claims define this variable as a bond of a divalent linking group. This definition does not state what elements are part of the linking group. Although this variables is discussed in the specification, the recited groups do not limit claim 1 (specification, page 24, paragraphs 3 and 4). The structural metes and bounds of variables Pol1 to Pol4 are unclear. The claims define them each as H or a polymerizable group. This claims do define what elements constitute a polymerizable group. Although these variables are discussed in the specification, the recited groups do not limit claim 1 (specification, page 16, paragraph [0038] to paragraph [0040]). The structural metes and bounds of variables rings Ar11 and Ar12 are unclear because the term “including” is equivalent to “comprising” [see MPEP 2111.03 (I)]. The claims do not recite what other groups can be present beside a benzene ring or a heteroaromatic heterocyclic group. What # is referred to for variables Xa and Xb in relation to general formula (A)? When N is a substituent of a CH group for variable Xa or Xb, it has an unfilled octet and consequently the groups attached to it are not clear. Claims 1-16 recite the limitation that linking groups Spa, Spb, and Spc contain a methylene group. There is insufficient antecedent basis for these limitation in the claims because the first recitation of each of these variables does not recite what elements are part of each linking group. Conclusion Claims 1-16 are not allowed. The following is a statement of reasons for the indication of allowable subject matter: XU (US 20140322549, published 2014 October 30) describes a composition comprising benzyl methacrylate and trimethyolpropane triacrylate (page 3, paragraph [0045]; page 4, paragraph [0056]). The benzyl methacrylate has no acidic group nor is a near-ultraviolet light absorbing compound present either. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Dec 29, 2022
Application Filed
Dec 17, 2025
Non-Final Rejection mailed — §112
Mar 13, 2026
Response Filed
May 27, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12704504
DERIVATIZATION OF BETA-LACTAM ANTIBIOTICS AS CALIBRATORS/ISTD IN MASSSPEC MEASUREMENTS
4y 2m to grant Granted Aug 11, 2026
Patent 12697402
DETECTION OF COLONIC NEOPLASIA IN VIVO USING NEAR-INFRARED PEPTIDE TARGETED AGAINST OVEREXPRESSED CMET
4y 11m to grant Granted Aug 04, 2026
Patent 12691182
MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
3y 11m to grant Granted Jul 28, 2026
Patent 12679841
PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
4y 7m to grant Granted Jul 14, 2026
Patent 12679858
METAL IRIDIUM COMPLEX AND USE THEREOF
3y 7m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+9.6%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1034 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month